DMARD治療を受けた若年性イディオパシー関節炎患者における健康関連生活の質と,一般の患者との比較
Imane Bardan1, Till Uhlig2, Joe Sexton3
1I. Bardan, MD, Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
The Journal of rheumatology
|September 1, 2025
まとめ
ジュベニアル・イディオパシー・関節炎 (JIA) の成人は,リウマチ性関節炎 (RA) と一般の人々と比較して,身体的な生活の質が低い. 比較可能な治療改善が見られた.
科学分野:
- リウマトロジ
- 臨床流行病学
- 健康 成果 研究
背景:
- ジュベニアル・イディオパシー・関節炎 (JIA) は,子供に影響を与える慢性的な自己免疫疾患で,しばしば成人期まで持続します.
- JIAの成人は,健康関連の生活の質 (HRQoL) の低下を含む長期の健康上の影響を経験する可能性があります.
- 成人のJIAにおけるHRQoLの理解は,効果的な管理と患者中心のケアに不可欠です.
研究 の 目的:
- JIA と関節リウマチ (RA) の成人のHRQoLを比較する.
- 短いフォーム36 (SF-36),SF-36の身体コンポーネントスコア (PCS),SF-36のメンタルコンポーネントスコア (MCS),および短いフォーム6D (SF-6D) を使用してHRQoLを評価します.
- 治療によるHRQoLの改善を評価するために,病変変性抗レウマチ薬 (DMARD) 治療の6ヶ月後.
主な方法:
- ノルウェーの疾患修正抗レウマティック薬 (NOR-DMARD) 試験の6ヶ月の追跡データを活用した.
- JIAとRAの成人患者で,DMARD治療を開始または変更した患者も含まれています.
- 年齢と性別を調整した回帰分析を比較結果評価のために使用した.
主要な成果:
- JIAの患者は,RAの患者と比較して,身体的要素のスコア (PCS) が低いが,精神的要素のスコア (MCS) は同様であった.
- JIAとRAの2つのグループは,一般人よりもPCSが著しく低く,MCSは比較可能なままでした.
- SF-6Dの効用レベルは,JIAとRAの間で類似したが,一般人群より低い.両方のグループは,臨床的に重要な最小限の違い (MCID) を超える同様の改善を示した.
結論:
- 大人のJIAは,RAと一般の人々と比較して,DMARD開始後6ヶ月間の身体HRQoLの低下と関連しています.
- 精神疾患の構成要素は,JIA,RA,および一般集団で比較可能でした.
- JIAとRAの両方の患者グループは,HRQoLの測定値で同様の治療による改善を達成しました.
関連する概念動画
01:21Rheumatic Heart Disease III: Medical Management
31
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
31
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
57
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
57
01:23Rheumatic Heart Disease I: Introduction
38
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
38
01:21Dimensions of Health and Illness
8.2K
The factors influencing the health-illness continuum can be internal or external and may or may not be under conscious control. They are related to the following eight human dimensions, and each dimension is interrelated to one other.
8.2K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
264
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
264
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
201
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
201